Print Page   |   Sign In   |   Join!
News & Press: Legislative and Regulatory News

Adverse Events Linked to Sterile Products: Your Action Needed to Prevent Further Patient Harm

Monday, August 12, 2013  
Posted by: William O'Hara
Share |
Patient harm arising from contaminated product from a Texas compounder underscores the urgent need for ASHP members to build support for the Pharmaceutical Quality, Security, and Accountability Act, S. 959. FDA hasadvisedhealth professionals to stop using sterile products supplied by Specialty Compounding in Cedar Park, Texas. The agency received reports of adverse events experienced by 15 patients in two hospitals. This incident emphasizes the need for ASHP members tocontacttheir two senators and ask them to vote "yes" for S. 959, legislation that will close regulatory gaps in the oversight of sterile compounding.Learn more

Membership Management Software Powered by YourMembership  ::  Legal